Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases

BACKGROUND: Intraperitoneal (IP) administration of paclitaxel (PTX) has a great pharmacokinetic advantage to control peritoneal lesions and can be combined with various systemic chemotherapies. In this study, we evaluate the efficacy and tolerability of a combination of IP-PTX and systemic S-1/oxali...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shin, Yamaguchi, Hironori, Ohzawa, Hideyuki, Miyato, Hideyo, Kanamaru, Rihito, Kurashina, Kentaro, Hosoya, Yoshinori, Lefor, Alan Kawarai, Sata, Naohiro, Kitayama, Joji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Peritoneal Surface Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184712/
https://www.ncbi.nlm.nih.gov/pubmed/33270170
http://dx.doi.org/10.1245/s10434-020-09388-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184712/
https://www.ncbi.nlm.nih.gov/pubmed/33270170
http://dx.doi.org/10.1245/s10434-020-09388-4

Ejemplares similares